Shots:
- JCR to receive an up front for the Ex-US license & additional development & commercial milestones along with royalties on the sales of JR-141
- Takeda will exclusively commercialize JR-141 outside of the US, including the EU, Canada & other regions (Ex-Japan and other Asia-Pacific countries). Additionally, Takeda has entered into an option agreement under which it receives an option to obtain an exclusive license to commercialize the therapy in the US, following completion of the P-III program
- JR-141 is a recombinant fusion protein of an Ab against human TfR & IDS enzyme. The results from the P-II/III trial demonstrated a reduction in HS in the CSF & improvement in somatic symptoms
Click here to read full press release/ article | Ref: Businesswire | Image: The Japan Times
The post Takeda Signs an Exclusive License Agreement with JCR to Commercialize JR-141 for the Treatment of Hunter Syndrome first appeared on PharmaShots.
